Inaktiver Wert

Andere Sprachen Natco Pharma Ltd. NSE India S.E.

Aktien

INE987B01018

Schlusskurs NSE India S.E. Andere Börsenplätze
- ^INR	-

28.05.	INDISCHE AKTIEN - Metall- und Pharmatitel treiben indische Benchmarks nach oben	RE
28.05.	Transcript : NATCO Pharma Limited, Q4 2024 Earnings Call, May 28, 2024

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

INDIA STOCKS-Metal, pharma stocks drive Indian benchmarks higher	28.05.
Transcript : NATCO Pharma Limited, Q4 2024 Earnings Call, May 28, 2024	28.05.
NATCO Pharma Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	27.05.
NATCO Pharma Limited Reports Earnings Results for the Full Year Ended March 31, 2024	27.05.
AstraZeneca, Merck Sue to Protect Lynparza Cancer Drug Patents	08.05.
AstraZeneca, Merck Sue to Protect Lynparza Cancer Drug Patents	08.05.
AstraZeneca, Merck Sue Over Alleged Cancer Drug Patents Infringement	08.05.
Natco Pharma Gets US FDA Warning Letter after Inspection of Kothur, India Unit	09.04.
NATCO Pharma Limited Announces Board Appointments	27.03.
INDIA STOCKS-Indian shares erase early gains, weighed down by IT stocks	19.02.
NATCO Pharma Limited Revises Earnings Guidance for the Fiscal Year 2024	15.02.
Transcript : NATCO Pharma Limited, Q3 2024 Earnings Call, Feb 15, 2024	15.02.
Corporate Action-Board Approves Third Interim Dividend for the Financial Year 2023-24, Payable on 4 March 2024	14.02.
NATCO Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	14.02.
Floods Disrupt Operations of Natco Pharma's Plant in Tamil Nadu, India	07.12.
Transcript : NATCO Pharma Limited, Q2 2024 Earnings Call, Nov 15, 2023	15.11.
Natco Pharma's Consolidated Profit Soars in Fiscal Q2, Declares Second Interim Dividend	14.11.
NATCO Pharma Limited Declares Second Interim Dividend for the Financial Year 2023-24, Payable on 1 December, 2023	14.11.
NATCO Pharma Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	14.11.
US FDA Clears Natco Pharma's Pharmacovigilance Department in Hyderabad, India	02.11.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Natco Pharma Ltd. NSE India S.E.

Aktien

INE987B01018

Andere Sprachen

Filter